Description

Oral cholesterol-lowering agent.

For the treatment of hypercholesterolaemia (primary hypercholesterolaemia and hypertriglyceridemia I, II, III and IV) and as an adjunct in the prevention of ischemic heart disease (angina pectoris, unstable angina pectoris and myocardial infarction), decreased risk of stroke and transient ischemic attacks (TIA).

Coronary heart disease: In patients with coronary heart disease, simvastatin is indicated for:

• Reduce the risk of death from coronary causes and non-fatal myocardial infarction.

• Lower the risk of stroke and transient ischemic attacks (TIA).

• Reduce the likelihood of needing myocardial revascularization operations (coronary bypass graft or percutaneous transluminal coronary angioplasty).

• Slow the progression of coronary atherosclerosis, including the development of new lesions and total occlusions.

Hyperlipidemia: Simvastatin is indicated as a dietary supplement to lower elevated total cholesterol, LDL cholesterol, triglycerides and apolipoproteins B (apo B) and to increase HDL cholesterol in patients with primary hypercholesterolemia, including hypercholesterolemia. heterozygous familial (Fredrickson type IIa) or combined hyperlipidemia (mixed [Fredrickson type IIb]) when response to diet and other non-pharmacological measures alone has been insufficient. Simvastatin, therefore, lowers the LDL / HDL and total / HDL cholesterol ratios.

Simvastatin is indicated for the treatment of patients with hypertriglyceridaemia (Fredrickson type IV hyperlipidaemia).

It is also indicated in the treatment of patients with primary dysbetalipoproteinemia (Fredrickson’s type III hyperlipidemia).

Simvastatin is indicated as a supplement to diet and other non-pharmacological measures in the treatment of patients with homozygous familial hypercholesterolemia to lower elevated total cholesterol, LDL cholesterol, and apolipoproteins B.